In this episode of The GLP-1 Podcast Show, I speak with Dr. Richard DiMarchi, Distinguished Professor at Indiana University and a pioneer in peptide therapeutics, about the scientific journey behind GLP-1 therapies, multiagonist drug development, and future obesity treatments. We explore glucagon, GIP, triple agonists, and emerging innovations shaping metabolic medicine. Listen now on all major platforms!
"For decades, glucagon was viewed primarily as a hormone that raises blood glucose. Research later revealed that glucagon could also promote weight reduction and improve liver metabolism when balanced appropriately with GLP-1 activity."
Meet the guest: Dr. Richard DiMarchi is a Distinguished Professor at Indiana University and a recognized leader in peptide therapeutics, diabetes research, and obesity medicine. His work contributed to major advances in insulin, glucagon, and multiagonist therapies, while also helping establish several biotechnology companies. Dr. DiMarchi continues to advance innovation in the treatment of metabolic diseases through research and translational science. Listen to Dr. Richard DiMarchi on The GLP-1 Podcast Show, available on all major platforms.
What you will learn:
- (00:00) Highlight
- (01:19) Introduction
- (05:31) GLP-1 evolution
- (09:16) Multiagonist design
- (15:46) Glucagon controversy
- (17:42) GIP role
- (24:32) Future treatments
- (30:13) Final Questions
๐๐ถ๐๐๐ฒ๐ป ๐ผ๐ป ๐๐ฝ๐ฝ๐น๐ฒ ๐ฃ๐ผ๐ฑ๐ฐ๐ฎ๐๐๐, ๐ฆ๐ฝ๐ผ๐๐ถ๐ณ๐ ๐ผ๐ฟ ๐ฎ๐ป๐ ๐บ๐ฎ๐ท๐ผ๐ฟ ๐ฝ๐น๐ฎ๐๐ณ๐ผ๐ฟ๐บ.
Website: The GLP-1 Podcast Show
Instagram: The GLP-1 Podcast Show
LinkedIn: The GLP-1 Podcast Show
YouTube: The GLP-1 Podcast Show
Facebook: The GLP-1 Podcast Show
TikTok: The GLP-1 Podcast Show
